144 related articles for article (PubMed ID: 38494800)
1. [History and Perspective of Chemotherapy in Advanced Esophageal Cancer].
Shiraishi K; Kato K
Gan To Kagaku Ryoho; 2024 Mar; 51(3):240-244. PubMed ID: 38494800
[TBL] [Abstract][Full Text] [Related]
2. Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer.
Kadono T; Yamamoto S; Kato K
Jpn J Clin Oncol; 2022 Oct; 52(10):1089-1096. PubMed ID: 36047845
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
Doki Y; Ajani JA; Kato K; Xu J; Wyrwicz L; Motoyama S; Ogata T; Kawakami H; Hsu CH; Adenis A; El Hajbi F; Di Bartolomeo M; Braghiroli MI; Holtved E; Ostoich SA; Kim HR; Ueno M; Mansoor W; Yang WC; Liu T; Bridgewater J; Makino T; Xynos I; Liu X; Lei M; Kondo K; Patel A; Gricar J; Chau I; Kitagawa Y;
N Engl J Med; 2022 Feb; 386(5):449-462. PubMed ID: 35108470
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Kang YK; Chen LT; Ryu MH; Oh DY; Oh SC; Chung HC; Lee KW; Omori T; Shitara K; Sakuramoto S; Chung IJ; Yamaguchi K; Kato K; Sym SJ; Kadowaki S; Tsuji K; Chen JS; Bai LY; Oh SY; Choda Y; Yasui H; Takeuchi K; Hirashima Y; Hagihara S; Boku N
Lancet Oncol; 2022 Feb; 23(2):234-247. PubMed ID: 35030335
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab: first anti-PD-1/L1-based regimen for first-line treatment of advanced esophageal cancer in Japan.
Harada K; Yamamoto S; Kato K
Expert Opin Biol Ther; 2022 Nov; 22(11):1333-1338. PubMed ID: 36266954
[TBL] [Abstract][Full Text] [Related]
6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
7. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Fernández-Pello S; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Mar; 79(3):339-342. PubMed ID: 33357997
[TBL] [Abstract][Full Text] [Related]
8. Adverse event costs associated with first-line therapy for advanced non-small cell lung cancer in the United States: An analysis of clinical trials of immune checkpoint inhibitors.
Stenehjem D; Lubinga SJ; Wu A; Betts KA
J Manag Care Spec Pharm; 2023 Sep; 29(9):1054-1064. PubMed ID: 37610116
[No Abstract] [Full Text] [Related]
9. Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).
Tintelnot J; Goekkurt E; Binder M; Thuss-Patience P; Lorenzen S; Knorrenschild JR; Kretzschmar A; Ettrich T; Lindig U; Jacobasch L; Pink D; Al-Batran SE; Hinke A; Hegewisch-Becker S; Nilsson S; Bokemeyer C; Stein A
BMC Cancer; 2020 Jun; 20(1):503. PubMed ID: 32487035
[TBL] [Abstract][Full Text] [Related]
10. Frontline BRAF Testing-Guided Treatment for Advanced Melanoma in the Era of Immunotherapies: A Cost-Utility Analysis Based on Long-term Survival Data.
Wu B; Shi L
JAMA Dermatol; 2020 Nov; 156(11):1177-1184. PubMed ID: 32697281
[TBL] [Abstract][Full Text] [Related]
11. The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care.
Bedke J; Albiges L; Capitanio U; Giles RH; Hora M; Lam TB; Ljungberg B; Marconi L; Klatte T; Volpe A; Abu-Ghanem Y; Dabestani S; Pello SF; Hofmann F; Kuusk T; Tahbaz R; Powles T; Bex A
Eur Urol; 2021 Oct; 80(4):393-397. PubMed ID: 34074559
[TBL] [Abstract][Full Text] [Related]
12. First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50).
Kato K; Doki Y; Ogata T; Motoyama S; Kawakami H; Ueno M; Kojima T; Shirakawa Y; Okada M; Ishihara R; Kubota Y; Amaya-Chanaga C; Chen T; Matsumura Y; Kitagawa Y
Esophagus; 2023 Apr; 20(2):291-301. PubMed ID: 36401133
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitor, Nivolumab, Combined with Chemotherapy Improved the Survival of Unresectable Advanced and Metastatic Esophageal Squamous Cell Carcinoma: A Real-World Experience.
Kao MW; Kuo YH; Hsieh KC; Lee CT; Wu SC; Yang WC
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108474
[TBL] [Abstract][Full Text] [Related]
14. Immuno-oncology for esophageal cancer.
Yamamoto S; Kato K
Future Oncol; 2020 Nov; 16(32):2673-2681. PubMed ID: 32777942
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab for the treatment of advanced esophageal cancer.
Harada K; Yamamoto S; Kato K
Future Oncol; 2022 Jun; 18(18):2311-2319. PubMed ID: 35418242
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A;
Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178
[TBL] [Abstract][Full Text] [Related]
17. Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma.
Moehler M; Högner A; Wagner AD; Obermannova R; Alsina M; Thuss-Patience P; van Laarhoven H; Smyth E
Eur J Cancer; 2022 Nov; 176():13-29. PubMed ID: 36183651
[TBL] [Abstract][Full Text] [Related]
18. Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E).
Yamamoto S; Kato K; Daiko H; Kojima T; Hara H; Abe T; Tsubosa Y; Nagashima K; Aoki K; Mizoguchi Y; Kitano S; Yachida S; Shiba S; Kitagawa Y
Future Oncol; 2020 Jul; 16(19):1351-1357. PubMed ID: 32396014
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma.
Zhang PF; Xie D; Li Q
Future Oncol; 2020 Jun; 16(17):1189-1198. PubMed ID: 32407173
[No Abstract] [Full Text] [Related]
20. [Unresectable Esophageal Cancer on the Elderly Woman Which Was Treated Effectively with Ipilimumab plus Nivolumab-A Case Report].
Fujii T; Suzuki T; Yamaguchi S; Shibata Y; Tazuma S; Akimoto S; Sada H; Shimada N; Tazawa H; Onoe T; Sudo T; Shimizu Y; Tashiro H
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1691-1693. PubMed ID: 38303175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]